Searched for: school:SOM
Department/Unit:Neuroscience Institute
Activity-dependent A-to-I RNA editing in rat cortical neurons
Sanjana, Neville E; Levanon, Erez Y; Hueske, Emily A; Ambrose, Jessica M; Li, Jin Billy
Changes in neural activity influence synaptic plasticity/scaling, gene expression, and epigenetic modifications. We present the first evidence that short-term and persistent changes in neural activity can alter adenosine-to-inosine (A-to-I) RNA editing, a post-transcriptional site-specific modification found in several neuron-specific transcripts. In rat cortical neuron cultures, activity-dependent changes in A-to-I RNA editing in coding exons are present after 6 hr of high potassium depolarization but not after 1 hr and require calcium entry into neurons. When treatments are extended from hours to days, we observe a negative feedback phenomenon: Chronic depolarization increases editing at many sites and chronic silencing decreases editing. We present several different modulations of neural activity that change the expression of different mRNA isoforms through editing.
PMCID:3430542
PMID: 22714409
ISSN: 1943-2631
CID: 2131252
Spinal cord stimulation protects against atrial fibrillation induced by tachypacing
Bernstein, Scott A; Wong, Brian; Vasquez, Carolina; Rosenberg, Stuart P; Rooke, Ryan; Kuznekoff, Laura M; Lader, Joshua M; Mahoney, Vanessa M; Budylin, Tatyana; Alvstrand, Marie; Rakowski-Anderson, Tammy; Bharmi, Rupinder; Shah, Riddhi; Fowler, Steven; Holmes, Douglas; Farazi, Taraneh G; Chinitz, Larry A; Morley, Gregory E
BACKGROUND: Spinal cord stimulation (SCS) has been shown to modulate atrial electrophysiology and confer protection against ischemia and ventricular arrhythmias in animal models. OBJECTIVE: To determine whether SCS reduces the susceptibility to atrial fibrillation (AF) induced by tachypacing (TP). METHODS: In 21 canines, upper thoracic SCS systems and custom cardiac pacing systems were implanted. Right atrial and left atrial effective refractory periods were measured at baseline and after 15 minutes of SCS. Following recovery in a subset of canines, pacemakers were turned on to induce AF by alternately delivering TP and searching for AF. Canines were randomized to no SCS therapy (CTL) or intermittent SCS therapy on the initiation of TP (EARLY) or after 8 weeks of TP (LATE). AF burden (percent AF relative to total sense time) and AF inducibility (percentage of TP periods resulting in AF) were monitored weekly. After 15 weeks, echocardiography and histology were performed. RESULTS: Effective refractory periods increased by 21 +/- 14 ms (P = .001) in the left atrium and 29 +/- 12 ms (P = .002) in the right atrium after acute SCS. AF burden was reduced for 11 weeks in EARLY compared with CTL (P <.05) animals. AF inducibility remained lower by week 15 in EARLY compared with CTL animals (32% +/- 10% vs 91% +/- 6%; P <.05). AF burden and inducibility were not significantly different between LATE and CTL animals. There were no structural differences among any groups. CONCLUSIONS: SCS prolonged atrial effective refractory periods and reduced AF burden and inducibility in a canine AF model induced by TP. These data suggest that SCS may represent a treatment option for AF.
PMCID:3634125
PMID: 22554859
ISSN: 1547-5271
CID: 177139
High frequency oscillations in the intact brain
Buzsaki, G; Silva, FL
High frequency oscillations (HFOs) constitute a novel trend in neurophysiology that is fascinating neuroscientists in general, and epileptologists in particular. But what are HFOs? What is the frequency range of HFOs? Are there different types of HFOs, physiological and pathological? How are HFOs generated? Can HFOs represent temporal codes for cognitive processes? These questions are pressing and this symposium volume attempts to give constructive answers. As a prelude to this exciting discussion, we summarize the physiological high frequency patterns in the intact brain, concentrating mainly on hippocampal patterns, where the mechanisms of high frequency oscillations are perhaps best understood.
PMCID:4895831
PMID: 22449727
ISSN: 0301-0082
CID: 169688
The Learning Disabilities Network (LeaDNet): using neurofibromatosis type 1 (NF1) as a paradigm for translational research
Acosta, Maria T; Bearden, Carrie E; Castellanos, F Xavier; Cutting, Laurie; Elgersma, Ype; Gioia, Gerard; Gutmann, David H; Lee, Yong-Seok; Legius, Eric; Muenke, Maximillian; North, Kathryn; Parada, Luis F; Ratner, Nancy; Hunter-Schaedle, Kim; Silva, Alcino J
Learning disabilities and other cognitive disorders represent one of the most important unmet medical needs and a significant source of lifelong disability. To accelerate progress in this area, an international consortium of researchers and clinicians, the Learning Disabilities Network (LeaDNet), was established in 2006. Initially, LeaDNet focused on neurofibromatosis type 1 (NF1), a common single gene disorder with a frequency of 1:3,000. Although NF1 is best recognized as an inherited tumor predisposition syndrome, learning, cognitive, and neurobehavioral deficits account for significant morbidity in this condition and can have a profound impact on the quality of life of affected individuals. Recently, there have been groundbreaking advances in our understanding of the molecular, cellular, and neural systems underpinnings of NF1-associated learning deficits in animal models, which precipitated clinical trials using a molecularly targeted treatment for these deficits. However, much remains to be learned about the spectrum of cognitive, neurological, and psychiatric phenotypes associated with the NF1 clinical syndrome. In addition, there is a pressing need to accelerate the identification of specific clinical targets and treatments for these phenotypes. The successes with NF1 have allowed LeaDNet investigators to broaden their initial focus to other genetic disorders characterized by learning disabilities and cognitive deficits including other RASopathies (caused by changes in the Ras signaling pathway). The ultimate mission of LeaDNet is to leverage an international translational consortium of clinicians and neuroscientists to integrate bench-to-bedside knowledge across a broad range of cognitive genetic disorders, with the goal of accelerating the development of rational and biologically based treatments.
PMCID:4074877
PMID: 22821737
ISSN: 1552-4825
CID: 422652
Commentary on "Electrophysiological Properties of in vitro Purkinje Cell Dendrites in Mammalian Cerebellar Slices. J Physiol 1980;305:197-213."
Llinas, Rodolfo R
PMID: 22696291
ISSN: 1473-4222
CID: 178178
"Untangling" Alzheimer's disease and epilepsy
Scharfman, Helen E
There is a substantial body of evidence that spontaneous recurrent seizures occur in a subset of patients with Alzheimer disease (AD), especially the familial forms that have an early onset. In transgenic mice that simulate these genetic forms of AD, seizures or reduced seizure threshold have also been reported. Mechanisms underlying the seizures or reduced seizure threshold in these mice are not yet clear and are likely to be complex, because the synthesis of amyloid beta (Abeta) involves many peptides and proteases that influence excitability. Based on transgenic mouse models of AD where Abeta and its precursor are elevated, it has been suggested that seizures are caused by the downregulation of the Nav1.1 sodium channel in a subset of GABAergic interneurons, leading to a reduction in GABAergic inhibition. Another mechanism of hyperexcitability appears to involve tau, because deletion of tau reduces seizures in some of the same transgenic mouse models of AD. Therefore, altered excitability may be as much a characteristic of AD as plaques and tangles-especially for the familial forms of AD.
PMCID:3482723
PMID: 23118602
ISSN: 1535-7511
CID: 210442
Capital Punishment: What Is the Appropriate Abbreviation for Partial Pressure of a Gas?
Kenny, Jon-Emile; Goldfarb, David S
PMID: 22739555
ISSN: 0002-9629
CID: 175745
TAILORED INHIBITION OF CYSTINE STONE FORMATION AS A THERAPY FOR CYSTINURIA [Meeting Abstract]
Sahota, A.; Yang, M.; Shikhel, S.; Lewis, M. R.; Goldfarb, D. S.; Ward, M. D.; Tischfield, J. A.
ISI:000307513100087
ISSN: 0141-8955
CID: 177760
NAPA 2.0: the next giant leap [Editorial]
Khachaturian, Ara S; Paul, Steven M; Khachaturian, Zaven S
PMID: 22959697
ISSN: 1552-5260
CID: 936602
Thalamus and cognitive impairment in Mild Traumatic Brain Injury: A Diffusional Kurtosis Imaging Study
Grossman EJ; Ge Y; Jensen JH; Babb JS; Miles L; Reaume J; Silver JM; Grossman RI; Inglese M
Conventional imaging is unable to detect damage that accounts for permanent cognitive impairment in patients with mild traumatic brain injury (MTBI). While diffusion tensor imaging (DTI) can help to detect diffuse axonal injury (DAI), it is a limited indicator of tissue complexity. It has also been suggested that the thalamus may play an important role in the development of clinical sequelae in MTBI. The purpose of this study was to determine if diffusional kurtosis imaging (DKI), a novel quantitative magnetic resonance imaging (MRI) technique, can provide early detection of damage in the thalamus and white matter (WM) of MTBI patients and if thalamic injury is associated with cognitive impairment. Twenty-two MTBI patients and 14 controls underwent MRI and neuropsychological testing. Mean kurtosis (MK), fractional anisotropy (FA), and mean diffusivity (MD) were measured in the thalamus and several WM regions classically identified with DAI. Compared to controls, patients examined within one year after injury exhibited variously altered DTI and DKI derived measures in the thalamus and the internal capsule while, in addition to these regions, patients examined more than one year after injury also showed similar differences in the splenium of the corpus callosum and the centrum semiovale. Cognitive impairment was correlated to MK in the thalamus and the internal capsule. These findings suggest that combined use of DTI and DKI provides a more sensitive tool for identifying brain injury. In addition, MK in the thalamus might be useful for early prediction of permanent brain damage and cognitive outcome
PMCID:3430483
PMID: 21639753
ISSN: 1557-9042
CID: 135641